Insmed

What Insmed does

Insmed is a commercial-stage biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, that develops and commercializes therapies for serious and rare diseases, with a primary focus on pulmonary and inflammatory conditions. The company markets two FDA-approved products: ARIKAYCE (amikacin liposome inhalation suspension), approved in 2018 as the only therapy for refractory Mycobacterium avium complex (MAC) lung disease in the US, Europe, and Japan; and BRINSUPRI (brensocatib), approved in August 2025 as the first and only therapy for non-cystic fibrosis bronchiectasis (NCFB), a condition with approximately 500,000 diagnosed US patients and no dedicated treatment for over 200 years. The company also pursues a pipeline spanning pulmonary arterial hypertension (TPIP), gene therapy candidates for Duchenne muscular dystrophy, ALS, and Stargardt disease (INS1201/1202/1203), the next-generation DPP1 inhibitor INS1033, and a recently acquired anti-SCF248 monoclonal antibody (INS1148) for ILD and asthma.

Insmed's technology foundation is built on multiple proprietary platforms: synthetic rescue technology (acquired via the Adrestia Therapeutics transaction in June 2023), protein deimmunization, RNA end-joining, and AAV9-mediated gene therapy with targeted delivery. Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor addressing neutrophil-mediated inflammation. The company operates four global research sites (New Jersey, New Hampshire, San Diego, Cambridge UK) and approximately 1,700 employees across nine offices in the US, Europe, and Japan.

The business model relies on prescription pharmaceutical sales through specialty pharmacy distribution to pulmonologists, infectious disease specialists, and respiratory therapists, with reimbursement from insurance, Medicare, and government payers. Full-year 2025 revenue reached $606.4 million ($433.8 million ARIKAYCE plus $172.7 million BRINSUPRI), with Q1 2026 revenue of $306.0 million representing 230% year-over-year growth. 2026 revenue guidance of $1.45-1.47 billion (BRINSUPRI at least $1 billion plus ARIKAYCE $450-470 million) signals an inflection from a single-product company to a multi-product respiratory franchise. The company has raised over $2.7 billion across multiple public equity and debt offerings between 2021 and 2025, and holds approximately $1.4 billion in cash, cash equivalents, and marketable securities.

Name

Insmed

Legal name

Insmed Incorporated

Website

https://insmed.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Insmed is a commercial-stage biopharmaceutical company developing and commercializing therapies for rare and serious pulmonary diseases, with two FDA-approved products (ARIKAYCE and BRINSUPRI) and a pipeline spanning gene therapy, synthetic rescue, and inflammation targets serving rare disease patient populations globally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Rare disease therapeutics
• Pulmonary biopharmaceuticals
• Inhaled antibiotic therapies
• Respiratory disease medicines
• Gene therapy pipeline

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ARIKAYCE Sales: ARIKAYCE (amikacin liposome inhalation suspension) generates recurring revenue from sales to patients with refractory MAC lung disease. Approved in US (2018), Europe (2020), and Japan (2021). Full-year 2025 revenues of $433.8 million, up 19% year-over-year, exceeding guidance. 2026 guidance: $450-470 million.
2. BRINSUPRI Sales: BRINSUPRI (brensocatib) launched in US in August 2025 following FDA approval for non-cystic fibrosis bronchiectasis. European approval received November 2025. Generated $172.7 million in 2025 revenues. Strong early launch with $144.6 million in Q4 2025. 2026 guidance: at least $1 billion.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Insmed is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes therapies for serious and rare pulmonary and inflammatory diseases. Its approved portfolio includes ARIKAYCE (amikacin liposome inhalation suspension) for refractory MAC lung disease and BRINSUPRI (brensocatib), a first-in-class DPP-1 inhibitor for non-cystic fibrosis bronchiectasis. The pipeline spans respiratory, immunology, and rare neurological disease programs including TPIP for pulmonary arterial hypertension and gene therapy candidates for Duchenne muscular dystrophy and ALS.

Product overview

Insmed is a biopharmaceutical company with two FDA-approved commercial therapies and a diverse pipeline of investigational medicines. Its commercial portfolio includes ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibiotic for refractory MAC lung disease generating $433.8 million in 2025 revenues, and BRINSUPRI (brensocatib), a first-in-class DPP-1 inhibitor approved in August 2025 as the first-ever treatment for non-cystic fibrosis bronchiectasis, generating $172.7 million in its first year. The company's pipeline spans three therapeutic areas: Respiratory (including TPIP for PAH and PH-ILD, INS1148 for ILD/asthma), Immunology & Inflammation (INS1033 for RA/IBD), and Neuro & Other Rare (gene therapies INS1201 for DMD, INS1202 for ALS, INS1203 for Stargardt disease). Insmed also developed InQuiry, an internal generative AI assistant for document processing and workflow automation.

Differentiator

Problem solved

Functional benefit

Brands

• ARIKAYCE: ARIKAYCE (amikacin liposome inhalation suspension) is Insmed's first approved therapy, indicated for adults with refractory Mycobacterium avium complex (MAC) lung disease. It is the first and only therapy approved for this condition in the U.S., Europe, and Japan.
• BRINSUPRI

Products and services

• ARIKAYCE (amikacin liposome inhalation suspension) Inhaled liposomal antibiotic indicated as the first and only therapy for adults with refractory Mycobacterium avium complex (MAC) lung disease, used in combination with a multidrug regimen. Full-year 2025 revenues were $433.8 million.
• BRINSUPRI (brensocatib) First-in-class dipeptidyl peptidase 1 (DPP-1) inhibitor and the first-ever approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older. Full-year 2025 revenues were $172.7 million.
• TPIP (treprostinil palmitil inhalation powder) Investigational inhaled prostacyclin therapy in development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• INS1201 (Gene Therapy for DMD) Investigational, intrathecally delivered micro-dystrophin AAV9 gene therapy being developed for patients with Duchenne muscular dystrophy.
• INS1202 (Gene Therapy for ALS) Investigational intrathecally delivered AAV9 short hairpin RNA construct targeting the human SOD1 gene, in development for ALS patients with SOD1 mutations and sporadic ALS.
• INS1203 (Gene Therapy for Stargardt Disease) Investigational gene therapy candidate targeting Stargardt disease, advancing toward the clinic.
• INS1148 (SCF248 Monoclonal Antibody) Monoclonal antibody targeting Stem Cell Factor 248 (SCF248), in development for interstitial lung disease and moderate to severe asthma.
• INS1033 (Next-Generation DPP1 Inhibitor) Next-generation dipeptidyl peptidase 1 (DPP1) inhibitor advancing toward the clinic for a range of neutrophil-mediated diseases, including rheumatoid arthritis and irritable bowel disease.

Quantifiable outcome

• BRINSUPRI reduced exacerbation frequency by 40-45% vs placebo in ASPEN Phase 3 trial
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

One partnership is on record.

• Adrestia TherapeuticscoreStrategic or Co-development Partner · 1 June 2023Insmed acquired Adrestia Therapeutics in June 2023, a UK-based biotech specialized in synthetic rescue therapies for genetic diseases. The deal included $72.4 million in shares and potential milestone payments up to $326.5 million, expanding Insmed's research capabilities into synthetic rescue platform technology.

Scale indicators20 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• United Therapeutics: Specialty biopharmaceutical company focused on pulmonary hypertension and rare pulmonary diseases. Highly relevant peer given Insmed's TPIP program directly competes with United Therapeutics' inhaled prostacyclin franchise (Tyvaso) in PAH and PH-ILD.
• Vertex Pharmaceuticals: Commercial-stage biopharma with a track record of launching first-in-class therapies for serious diseases (cystic fibrosis, sickle cell). Comparable as a rare/specialty disease commercial-stage biopharma scaling from a single-product base into a multi-asset franchise.
• BioMarin Pharmaceutical: Specialty biopharma focused on rare diseases with both small-molecule and gene therapy assets (e.g., Roctavian for hemophilia A). Directly comparable to Insmed in the rare-disease commercial-stage model and gene therapy pipeline ambitions.

Broad incumbents

• Alexion / AstraZeneca Rare Disease: Rare disease unit of AstraZeneca with Soliris/Ultomiris and Strensiq. Comparable as an established rare-disease specialty commercial player and potential acquirer/competitor in the same payer and prescriber channels Insmed targets.
• Genentech (Roche): Major biopharma with deep pulmonology and respiratory franchises (e.g., Esbriet, Actemra, Xolair) plus an active gene therapy pipeline. Comparable as a broad incumbent with overlapping respiratory and rare-disease therapeutic positions.
• Sanofi (Specialty Care / Rare Disease): Global biopharma with a large specialty and rare disease franchise (e.g., Dupixent in respiratory/inflammation, Genzyme rare disease unit). Overlaps with Insmed across respiratory biologics and rare-disease commercialization infrastructure.
• AstraZeneca: Global biopharma with major respiratory franchises (Symbicort, Fasenra, Trixeo) and rare-disease presence via Alexion. Previously licensed a product to Insmed, making it both a historical partner and broad incumbent competitor in respiratory.
• GSK: Major respiratory biopharma with Trelegy, Nucala, and other pulmonology assets, plus an active specialty/rare pipeline. Comparable as a broad incumbent competing for the same pulmonologist prescribers Insmed targets.

Others

• Insmed (peer reference: ARIKAYCE competitors in NTM/MAC lung) - Insmed is itself the topic; exclude:

Emerging players

• Arcturus Therapeutics: Late-stage clinical biopharma developing mRNA and inhaled therapeutics for rare pulmonary diseases (e.g., cystic fibrosis program). Comparable as an emerging player with overlapping inhaled/respiratory delivery technology targeting similar prescribers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Insmed
• YouTubeyoutube.com/@insmed
• LinkedInlinkedin.com/company/insmed
• Instagraminstagram.com/Insmed

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds17 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insmed